Meeting
2018 ASCO Annual Meeting
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
Authors
Mariano Provencio-Pulla
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Mariano Provencio-Pulla , Ernest Nadal-Alforja , Manuel Cobo , Amelia Insa , Marinha Costa Rivas , Margarita Majem , Delvys Rodriguez-Abreu , Guillermo Lopez-Vivanco , Manuel Domine , Elvira Del Barco Morillo , Bartomeu Massuti , Rosario Garcia Campelo , Alexandre Martinez Marti , Reyes Bernabé , Fernando Franco , Maria Jove , Ricardo Arrabal , Paloma Martin , Joaquin Casal , Virginia Calvo
Organizations
Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, Institut Català d’Oncologia, L’Hospitalet, Barcelona, Spain, Hospital Regional Universitario de Malaga, Malaga, Spain, Hospital Clinico Universitario de Valencia, Valencia, Spain, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, Hospital De Sant Pau, Barcelona, Spain, Hospital Universitavio Insular De Gran Canaria, Las Palmas, Spain, Department of Medical Oncology, Hospital de Cruces, Barakaldo, Spain, Oncology Department and Translational Oncology Division, University Hospital Fundacion Jimenez Diaz, Madrid, Spain, Complejo Asistencial Universitario de Salamanca, Oncology Department, Salamanca, Spain, Alicante University Hospital ISABIAL, Alicante, Spain, Medical Oncology Service, University Hospital A Coruña (XXIAC-SERGAS), A Coruña, Spain, Vall d'Hebron University Hospital, Barcelona, Spain, Hospital Universitario Virgen del Rocio, Sevilla, Spain, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, Medical Oncology Department, Institut Català d’Oncologia, l’Hospitalet de Llobregat, Barcelona, Spain, Thoracic Surgery Hospital Universitario Carlos Haya, Malaga, Spain, Hospital Clinico Universitario, Valencia, Spain, Hospital Universitario Puerta de Hierro, Madrid, Spain
Research Funding
Pharmaceutical/Biotech Company
Background: The combination of chemotherapy and immunotherapy (CT-IO) has a high response rate and longer survival in unselected patients (pts) with metastatic non-small cell lung cancer (NSCLC). There are no data about this combination in the neoadjuvant setting. Methods: A Phase II, single-arm, open-label multicenter study of resectable stage IIIA N2-NSCLC adult patients with CT plus IO (nivolumab (NV)) followed by adjuvant treatment for 1 year. Neoadjuvant treatment: Three cycles of NV 360mg IV Q3W + paclitaxel 200mg/m2 + carboplatin AUC 6 IV Q3W. After completing neoadjuvant therapy, tumor assessment is performed in patients prior to surgery. Surgery is performed in the 3rd or 4th week after day 21 of the third cycle of neoadjuvant treatment. Adjuvant treatment: nivolumab 240mg IV Q2W for 4 months and nivolumab 480mg IV Q4W for 8 months (total one year) after surgical resection. The study aims to recruit 46 pts. The primary endpoint is Progression-Free Survival (PFS) at 24 months. Efficacy is explored using objective pathologic response criteria. We present preliminary data on patients that completed 3 cycles and underwent surgical assessment. Results: At the time of submission, 30 pts had been included and 13 underwent surgery. CT-IO was well-tolerated and surgery was not delayed in any patient. None of the pts withdrew from the study preoperatively due to progression or toxicity. Thirteen surgeries had been performed and all tumors were deemed resectable. 9 cases (69.2%) achieved complete pathologic response (CPR) (CI 95% 38.6-90.9%), and 2 had a major pathologic response (MPR),defined as < 10% viable tumor cells in the resection specimen. Considering both CPR and MPR, the overall response rate was 84.6% (95% CI 54.6-98.1%). Conclusions: This is the first multicentric study testing CT-IO in the neoadjuvant setting with promising antitumor activity. Neoadjuvant CT-IO with nivolumab in resectable IIIA NSCLC yields a complete pathologic response rate that has never been seen previously. The data will be updated at the time of the congress. EudraCT Number: 2016-003732-20 Clinical trial information: NCT03081689
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03081689
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8521)
DOI
10.1200/JCO.2018.36.15_suppl.8521
Abstract #
8521
Poster Bd #
127
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Annual Meeting
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
First Author: Florian Guisier
Abstract
2023 ASCO Annual Meeting
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
First Author: Lisanne P. Zijlker
Abstract
2024 ASCO Annual Meeting
Predicting pathological response to neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer through liquid biopsy.
First Author: Siyu Lei
Abstract
2019 ASCO Annual Meeting
NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.
First Author: Mariano Provencio